ChemoCentryx Reports Second Quarter 2019 Financial Results and Recent Highlights
05 août 2019 16h05 HE
|
ChemoCentryx, Inc.
-- Topline data from pivotal ADVOCATE Phase III trial of C5a receptor inhibitor avacopan in ANCA Vasculitis on track for Q4 2019 -- -- Completed enrollment in LUMINA 1 Phase II trial of CCR2...
ChemoCentryx to Present at the Canaccord Genuity 39th Annual Growth Conference
01 août 2019 08h30 HE
|
ChemoCentryx, Inc.
MOUNTAIN VIEW, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the...
ChemoCentryx to Hold Second Quarter 2019 Financial Results Conference Call on Monday, August 5, 2019
31 juil. 2019 08h30 HE
|
ChemoCentryx, Inc.
MOUNTAIN VIEW, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's second quarter 2019 financial results will be released after market...
ChemoCentryx to Present at Two Upcoming Investor Conferences
11 juin 2019 08h30 HE
|
ChemoCentryx, Inc.
MOUNTAIN VIEW, Calif., June 11, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two...
ChemoCentryx Reports First Quarter 2019 Financial Results and Recent Highlights
06 mai 2019 16h05 HE
|
ChemoCentryx, Inc.
-- Succession of topline data readouts expected, starting with Pivotal ADVOCATE Phase III trial of C5a receptor inhibitor avacopan in ANCA Vasculitis in Q4 2019 -- -- Conference call today at 5:00...
ChemoCentryx to Hold First Quarter 2019 Financial Results Conference Call on Monday, May 6, 2019
29 avr. 2019 08h30 HE
|
ChemoCentryx, Inc.
MOUNTAIN VIEW, Calif., April 29, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's first quarter 2019 financial results will be released after market...
ChemoCentryx to Present at the H.C. Wainwright Global Life Sciences Conference
02 avr. 2019 08h30 HE
|
ChemoCentryx, Inc.
MOUNTAIN VIEW, Calif., April 02, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the...
ChemoCentryx Appoints Rita Jain, M.D. to Board of Directors
28 mars 2019 08h30 HE
|
ChemoCentryx, Inc.
MOUNTAIN VIEW, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), announced today that, effective March 27, 2019, Rita Jain, M.D., Senior Vice President and Chief Medical...
ChemoCentryx Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights
11 mars 2019 16h05 HE
|
ChemoCentryx, Inc.
-- Strong Progress Across Company’s Orphan Disease Franchise of Novel Renal and Dermal Therapeutics -- -- Pivotal top-line data expected from ADVOCATE Phase III trial of C5a receptor inhibitor...
ChemoCentryx to Hold Fourth Quarter 2018 Financial Results Conference Call on Monday, March 11, 2019
04 mars 2019 08h30 HE
|
ChemoCentryx, Inc.
MOUNTAIN VIEW, Calif., March 04, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's fourth quarter 2018 financial results will be released after market...